China National Accord Medicines Corporation Ltd. Sustainability Profile
China National Accord Medicines Corporation Ltd. (CNAM) is a prominent player in the pharmaceutical industry, headquartered in China. Established in 1997, the company has made significant strides in the development, production, and distribution of a wide range of pharmaceutical products, including traditional Chinese medicines and modern pharmaceuticals. With a strong operational presence across various regions in China, CNAM is dedicated to enhancing healthcare through innovative solutions. The company is recognised for its commitment to quality and efficacy, offering unique formulations that cater to diverse medical needs. As a leader in the sector, CNAM has achieved notable milestones, including numerous certifications and awards that underscore its market position. With a focus on research and development, CNAM continues to contribute to the advancement of healthcare in China and beyond.
DitchCarbon Score
How does China National Accord Medicines Corporation Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Retail Trade Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
China National Accord Medicines Corporation Ltd.'s score of 22 is lower than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
China National Accord Medicines Corporation Ltd., headquartered in CN, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Sinopharm Group Co. Ltd., which may influence its climate commitments and performance metrics. As of now, there are no documented reduction targets or climate pledges from China National Accord Medicines Corporation Ltd. This lack of specific initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. Given the absence of emissions data and reduction initiatives, it is essential for the company to establish clear climate commitments and targets to align with industry standards and expectations. This would not only enhance their sustainability profile but also contribute positively to the broader efforts in mitigating climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 30,741,540 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 88,611,470 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | 000,000,000 |
How Carbon Intensive is China National Accord Medicines Corporation Ltd.'s Industry?
How Carbon Intensive is China National Accord Medicines Corporation Ltd.'s Location?
China National Accord Medicines Corporation Ltd.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
China National Accord Medicines Corporation Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
